AN2 Therapeutics, Inc. (ANTX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.70
↑+65% vs avg
5yr avg: 1.64
30Y Low0.5·High3.9
ROE
↑
-52.1%
↓+7% vs avg
5yr avg: -55.9%
30Y Low-360%·High-50%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AN2 Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $130M | $34M | $41M | $484M | $146M | — | — | — |
| Enterprise Value | $110M | $15M | $20M | $468M | $119M | — | — | — |
| P/E Ratio → | -4.09 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.70 | 0.65 | 0.50 | 3.88 | 1.53 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ANTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
ANTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -52.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -52.1% | -52.1% | -49.7% | -58.8% | -52.1% | -66.6% | -359.7% | -702.5% |
| ROA | -45.7% | -45.7% | -44.5% | -53.7% | -48.8% | -61.9% | -273.9% | -593.2% |
| ROIC | -61.1% | -61.1% | -48.3% | -58.9% | -53.7% | -66.7% | — | — |
| ROCE | -56.4% | -56.4% | -52.8% | -63.3% | -53.7% | -66.7% | -175.2% | -560.7% |
ANTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $20M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | — | — | 0.15 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.38 | -0.26 | -0.13 | -0.28 | -0.20 | -1.48 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -79.68 | — | — | — |
Net cash position: cash ($20M) exceeds total debt ($0)
ANTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
AN2 Therapeutics, Inc.'s current ratio of 6.87x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.87x to 6.87x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.87 | 6.87 | 8.43 | 7.87 | 13.72 | 17.70 | 2.90 | 35.85 |
| Quick Ratio | 6.87 | 6.87 | 8.43 | 7.87 | 13.72 | 17.70 | 2.90 | 35.85 |
| Cash Ratio | 6.65 | 6.65 | 8.17 | 7.64 | 13.37 | 17.25 | 2.79 | 35.21 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
ANTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AN2 Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $30M | $30M | $24M | $15M | $19M | $19M | $19M |
Peer Comparison
Compare ANTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANTXYou | $130M | -4.1 | — | — | — | — | -52.1% | -61.1% | — |
 INSM | $21B | -15.3 | — | — | 79.4% | -194.0% | -249.3% | -86.5% | — |
 SPRO | $165M | 19.0 | — | — | 100.0% | -0.0% | 16.3% | -0.2% | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 ENTA | $276M | -3.1 | — | — | 93.0% | -130.7% | -84.6% | -23.2% | — |
 IDYA | $3B | -22.6 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 TARS | $3B | -39.0 | — | — | 93.2% | -15.7% | -23.4% | -23.4% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRL | $9B | -64.4 | 13.0 | 17.4 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $13B | 30.6 | 23.3 | 19.6 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 PFE | $149B | 19.3 | 10.6 | 16.4 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in ANTX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ANTX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ANTX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationANTX vs INSM — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Insmed Incorporated.
Compare NowANTX — Frequently Asked Questions
Quick answers to the most common questions about buying ANTX stock.
What is AN2 Therapeutics, Inc.'s P/E ratio?
AN2 Therapeutics, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.
What is AN2 Therapeutics, Inc.'s ROE?
AN2 Therapeutics, Inc.'s return on equity (ROE) is -52.1%. The historical average is -106.5%.
Is ANTX stock overvalued?
Based on historical data, AN2 Therapeutics, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.